| 1 |
NCT03811275 |
Recruiting |
Task or Virtual Reality Intervention for Improving UE Function |
- Upper Extremity Paresis
- Hemiplegia and/or Hemiparesis Following Stroke
- Hemiplegic Cerebral Palsy
|
- Behavioral: Virtual Reality (A) then Task (B)
- Behavioral: Task (B) then Virtual Reality (A)
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Change in Fugl-Meyer Assessment (UE portion)
- Change in Box & Block Test
- Change in Stroke Impact Scale 3.0
- (and 2 more...)
|
15 |
All |
18 Years to 89 Years (Adult, Older Adult) |
NCT03811275 |
IdahoSU |
|
September 8, 2018 |
August 1, 2020 |
August 1, 2020 |
January 21, 2019 |
January 21, 2019 |
|
- Nancy L Devine
Pocatello, Idaho, United States
|
|
| 2 |
NCT03793686 |
Recruiting |
A Study of Safety of PBCLN-003 Following Antibiotic Therapy in Subjects With C.Difficile-associated Diarrhea |
- Clostridium Difficile Diarrhea
|
- Drug: PBCLN-003
- Drug: Placebo
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Characterization of Adverse Events in a dose escalation study of PBCLN-003
|
48 |
All |
18 Years and older (Adult, Older Adult) |
NCT03793686 |
18-CT-001 |
|
December 6, 2018 |
October 2019 |
November 2019 |
January 4, 2019 |
April 4, 2019 |
|
- Infectious Disease Specialist
Idaho Falls, Idaho, United States
|
|
| 3 |
NCT03736395 |
Recruiting |
Scaling up Schoolwide Positive Behavioral Interventions and Supports (SWPBIS) in Rural Idaho Schools |
|
- Behavioral: Idaho Rural Implementation Model
- Behavioral: Control
|
Interventional
|
Not Applicable |
- Boise State University
- U.S. Department of Justice
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change over time in student disciplinary outcomes
- Change in student academic outcomes
- Fidelity of school implementation of positive behavioral interventions and supports (PBIS)
- Student perceptions of school climate
|
14000 |
All |
5 Years and older (Child, Adult, Older Adult) |
NCT03736395 |
2017-CK-BX-0021 |
I-RIM |
January 1, 2019 |
June 30, 2021 |
December 31, 2021 |
November 9, 2018 |
November 9, 2018 |
|
- Boise State University
Boise, Idaho, United States
|
|
| 4 |
NCT03686241 |
Recruiting |
The Use of a Dynamic Compression Intramedullary Nail for Tibiotalocalcaneal Arthrodesis |
- Ankle Arthritis
- Foot Arthritis
|
- Procedure: Tibiotalocalcaneal (TTC) arthrodesis
- Device: DynaNail
|
Observational
|
|
- MedShape, Inc
- Saint Alphonsus Medical Group
|
Industry / Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Fusion
- Pain - VAS
- Function - SF-36
- Function - FAAM
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT03686241 |
SARMC-SPS207720 |
|
May 22, 2017 |
May 2022 |
May 2022 |
September 26, 2018 |
September 28, 2018 |
|
- Saint Alphonsus Medical Group Orthopedics Coughlin Foot and Ankle Clinic
Boise, Idaho, United States
|
|
| 5 |
NCT03623100 |
Recruiting |
Neural Indices of Intervention Outcomes in Children With Speech Sound Disorders |
|
- Behavioral: Speech Production Treatment.
- Behavioral: Speech Production + Speech Perception Treatment.
|
Interventional
|
Not Applicable |
- Idaho State University
- National Institute on Deafness and Other Communication Disorders (NIDCD)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from baseline treated sound production accuracy at four months
- Change from baseline Mismatch Negativity (MMN) mean amplitude at four months
- Change from baseline P1/P2 mean amplitude at four months
- (and 4 more...)
|
60 |
All |
4 Years to 6 Years (Child) |
NCT03623100 |
R15DC013359
7R15DC013359 |
|
August 1, 2014 |
July 31, 2022 |
July 31, 2025 |
August 9, 2018 |
February 25, 2019 |
|
- Idaho State University - Meridian
Meridian, Idaho, United States
|
|
| 6 |
NCT03613818 |
Completed |
Efficacy of a Web-Based Alcohol Intervention for High School Students |
|
- Behavioral: eCHECKUP TO GO
|
Interventional
|
Not Applicable |
- Boise State University
- National Institutes of Health (NIH)
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Reduce Alcohol Use of High School Seniors
- Reduce Alcohol-Related Consequences of High School Seniors
|
313 |
All |
16 Years to 18 Years (Child, Adult) |
NCT03613818 |
023880
R21AA023880 |
|
October 1, 2018 |
March 15, 2019 |
March 15, 2019 |
August 3, 2018 |
April 9, 2019 |
|
- Boise State University
Boise, Idaho, United States
|
|
| 7 |
NCT03613662 |
Completed |
A Research Study to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102 |
- Lumbosacral Radicular Pain
|
|
Interventional
|
Phase 1 |
- Semnur Pharmaceuticals, Inc.
- Worldwide Clinical Trials
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in plasma cortisol in mcg/dL
- Change of white blood cell counts in 10^3/mcL
- Change in blood glucose in mg/dL
|
19 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03613662 |
SP-102-03 |
|
July 13, 2018 |
March 15, 2019 |
March 15, 2019 |
August 3, 2018 |
March 20, 2019 |
|
- Semnur Research Site 1
Boise, Idaho, United States
|
|
| 8 |
NCT03595566 |
Recruiting |
To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection |
- Clostridium Difficile Infection
|
- Drug: ridinilazole
- Drug: vancomycin
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Sustained clinical response defined as clinical cure at the Assessment of Cure (AOC) visit and no recurrence of CDI within 30 days post end of treatment (EOT)
- Clinical cure at Assessment of Cure (AOC) visit
- Sustained clinical response over 60 days
- (and 2 more...)
|
680 |
All |
18 Years and older (Adult, Older Adult) |
NCT03595566 |
SMT19969/C005 |
Ri-CoDIFy 2 |
January 28, 2019 |
June 2021 |
September 2021 |
July 23, 2018 |
May 7, 2019 |
|
- Snake River Research PLLC
Idaho Falls, Idaho, United States
|
|
| 9 |
NCT03440073 |
Completed |
Intervention for Pregnancy Related Pain |
- Other Specified Pregnancy-Related Conditions
|
- Other: Mulligan Concept Intervention
- Other: Sham Mulligan Concept Treatment
|
Interventional
|
Not Applicable |
- University of Idaho
- National Institutes of Health (NIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- 3-D motion Analysis- sit to stand
- 3-D Motion Analysis- gait
- 3-D Motion Analysis- active straight leg raise
- (and 7 more...)
|
36 |
Female |
20 Years to 45 Years (Adult) |
NCT03440073 |
17-042
18-22QR-UI-PG76 |
|
January 10, 2018 |
May 30, 2018 |
May 30, 2018 |
February 20, 2018 |
October 23, 2018 |
|
- Integrated Sport Medicine and Rehabilitative Therapy Clinic
Moscow, Idaho, United States
|
|
| 10 |
NCT02940587 |
Withdrawn |
Effectiveness of Aurix Therapy in Venous Leg Ulcers |
|
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to Heal
- Proportion of wounds healed
- Change in Quality of Life with Chronic Wounds (W-QOL) Score
|
0 |
All |
18 Years and older (Adult, Older Adult) |
NCT02940587 |
CM003 Gold |
|
February 2015 |
February 2018 |
February 2018 |
October 21, 2016 |
October 21, 2016 |
|
- St. Luke's Intermountain Research
Boise, Idaho, United States
|
|
| 11 |
NCT02921009 |
Recruiting |
McNeel Eye Center Corneal Crosslinking Study |
|
- Device: Crosslinking using UV light of two different fluence rates
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Post treatment topographic analysis of Crosslinked patients
- Post Treatment Best Corrected Visual Acuity
|
100 |
All |
15 Years to 50 Years (Child, Adult) |
NCT02921009 |
MEC CxL Transepithelial |
|
September 2016 |
December 2020 |
December 2020 |
September 30, 2016 |
March 13, 2019 |
|
- McNeel Eye Center
Boise, Idaho, United States
|
|
| 12 |
NCT02912351 |
Recruiting |
A Post-Market Retrospective Study on Revision Total Knee Arthroplasty Using Medacta GMK® Revision Prosthesis |
|
- Other: Patient record review, Radiographs, and questionaires.
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Total Knee Society Scores (KSS)
- Radiographic Analysis
- Patient Satisfaction
- Complication Assessment
|
50 |
All |
Child, Adult, Older Adult |
NCT02912351 |
K102437-01 |
|
January 2017 |
December 2021 |
December 2021 |
September 23, 2016 |
March 6, 2019 |
|
- Saint Alphonsus Medical Group
Boise, Idaho, United States
|
|
| 13 |
NCT02900248 |
Terminated |
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice |
- Neoplasms
- Lung Neoplasms
- Colon Neoplasms
- (and 22 more...)
|
- Other: Provider determined
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Best Overall Response
- Time to Treatment Progression
- Overall Survival
- (and 2 more...)
|
23 |
All |
18 Years and older (Adult, Older Adult) |
NCT02900248 |
N1OR |
N1 |
October 2, 2017 |
March 29, 2019 |
March 29, 2019 |
September 14, 2016 |
April 2, 2019 |
|
- Teton Cancer Institute
Idaho Falls, Idaho, United States
|
|
| 14 |
NCT02632929 |
Active, not recruiting |
Prevention of Amputation in Diabetic Foot Ulcers Using Amniotic Tissue |
|
|
Observational
|
|
- Boise VA Medical Center
- Integra LifeSciences Corporation
|
U.S. Fed / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Limb salvage
- effective wound healing
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT02632929 |
00816 |
|
July 2015 |
July 2019 |
September 2019 |
December 17, 2015 |
January 19, 2018 |
|
- Boise VAMC
Boise, Idaho, United States
|
|
| 15 |
NCT02363907 |
Completed
Has Results |
Observational Study to Evaluate the Effectiveness and Safety of the Dexcom G4 Continuous Glucose Monitoring System in Pediatrics |
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Point Accuracy of CGM ISF Readings to Blood Glucose Measured by a Reference Device
|
30 |
All |
2 Years to 17 Years (Child) |
NCT02363907 |
PTL-900982 |
|
September 2012 |
October 2012 |
October 2012 |
February 16, 2015 |
July 27, 2017 |
July 27, 2017 |
- Rocky Mountain Diabetes and Osteoporosis Center
Idaho Falls, Idaho, United States
|
|
| 16 |
NCT02330445 |
Completed |
6-Month Phase I/II Open Label PRTX-100 in Previous Rheumatoid Arthritis Study Participants and Sera Collection |
|
|
Interventional
|
Phase 1
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety (Analysis of Adverse Events)
- ACR-28 joint count
- Patient's global assessment of disease activity
- (and 14 more...)
|
13 |
All |
18 Years and older (Adult, Older Adult) |
NCT02330445 |
PRTX-100-105 |
SPARTA-II |
February 2015 |
April 18, 2016 |
November 30, 2016 |
January 5, 2015 |
October 16, 2018 |
|
- Protalex Investigational Site
Coeur d'Alene, Idaho, United States
|
|
| 17 |
NCT02230085 |
Completed
Has Results |
Adherence Risk Indicator Validation Study |
|
- Other: Administration of the questionnaire and monitoring of CPAP adherence
|
Observational
|
|
- Fisher and Paykel Healthcare
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
110 |
All |
18 Years and older (Adult, Older Adult) |
NCT02230085 |
CIA-121 |
ARI |
September 2014 |
August 2015 |
December 2015 |
September 3, 2014 |
March 3, 2017 |
December 2, 2016 |
- EverythingCPAP
Boise, Idaho, United States
|
|
| 18 |
NCT02185001 |
Terminated |
Repair of Medial Patellofemoral Ligament Compared to Conservative Treatment for First Time Patella Dislocation |
- Dislocated Patella
- Torn Medial Patellofemoral Ligament
|
- Procedure: Direct Medial Patellofemoral Ligament (MPFL) Repair
- Procedure: Physical therapy
|
Interventional
|
Not Applicable |
- Orthopedic Specialty Institute
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Patient Reported Change in Patellar Stability, Subluxation, or Recurrent Dislocation.
- Subjective Outcome Measurement (Kujala Test)
|
2 |
All |
10 Years and older (Child, Adult, Older Adult) |
NCT02185001 |
TLKC-0001 |
|
October 2014 |
March 2016 |
March 2016 |
July 9, 2014 |
March 9, 2017 |
|
- The Lyman Knee Clinic
Coeur d'Alene, Idaho, United States
|
|
| 19 |
NCT02170558 |
Withdrawn |
Enhanced Metal Reduction Techniques for Definitive CT Scanning to Assess Spinal Fusion With TM-Ardis |
- Degenerative Disc Disease
|
- Device: TM- Ardis implant and Metal Reduction CT software
|
Observational
|
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- CT scan to determine if the study software can reduce metal scatter on the scan.
|
0 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT02170558 |
CSU2013-05S |
|
June 2014 |
December 2015 |
December 2015 |
June 23, 2014 |
January 24, 2019 |
|
- St Alphonsus Regional Medical Center
Boise, Idaho, United States
|
|
| 20 |
NCT02121769 |
No longer available |
Omegaven Expanded Access Protocol |
- Parenteral Nutrition Associated Liver Disease
|
|
Expanded Access
|
|
- St. Luke’s Health System, Boise, Idaho
|
Other |
|
|
|
All |
up to 17 Years (Child) |
NCT02121769 |
Omegaven Expanded Access |
|
|
|
|
April 24, 2014 |
April 10, 2019 |
|
- St. Luke's Pediatric Gastroenterology
Boise, Idaho, United States
|
|
| 21 |
NCT02091804 |
Active, not recruiting |
Beginning Relationships in a Native Community |
|
- Behavioral: Immediate Group
- Behavioral: Wait-List group
|
Interventional
|
Not Applicable |
- University of Washington
- National Institute on Minority Health and Health Disparities (NIMHD)
- Washington State University
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Other
|
- Change in Quality of caregiver-child interactions from baseline at 3 months and 6 months
- Change in Caregiver helplessness from baseline at 3 months and 6 months
- Change in Caregiver stress from baseline at 3 months and 6 months
- Change in Child Social-emotional Competence from baseline at 3 months and 6 months
|
34 |
All |
Child, Adult, Older Adult |
NCT02091804 |
45360
1P20MD006871 |
P20-RP3 |
September 2014 |
May 2017 |
May 2018 |
March 19, 2014 |
October 26, 2017 |
|
- Nimiipuu Health Community Clinic
Lapwai, Idaho, United States
|
|
| 22 |
NCT01544283 |
Unknown † |
Pain Patch Versus Injections in the Treatment of Pain Associated With Shoulder Impingement Syndrome |
|
- Drug: Synera® (lidocaine 70 mg and tetracaine 70 mg) topical patch
- Drug: Triamcinolone Acetonide
|
Interventional
|
Phase 2 |
- Injury Care Medical Center
- Nuvo Research Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pain Intensity
- Patient Global Assessment of Treatment Satisfaction
- Patient Global Impression of Change
- (and 2 more...)
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT01544283 |
NS001 |
|
March 2012 |
January 2014 |
March 2014 |
March 5, 2012 |
March 6, 2012 |
|
- Injury Care Medical Center
Boise, Idaho, United States
|
|
| 23 |
NCT01514305 |
Completed |
Observational Study to Evaluate the Effectiveness and Safety Study of the Dexcom G4™ Continuous Glucose Monitoring System |
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Absolute Relative Difference (%) to Reference Standard
|
21 |
All |
18 Years and older (Adult, Older Adult) |
NCT01514305 |
PTL900830 |
|
November 2011 |
December 2011 |
December 2011 |
January 23, 2012 |
January 23, 2012 |
|
- Rocky Mountain Diabetes and Osteoporosis Center
Idaho Falls, Idaho, United States
|
|
| 24 |
NCT01341067 |
Completed
Has Results |
Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes |
|
|
Observational
|
|
- Rocky Mountain Diabetes and Osteoporosis Center
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change in HgbA1c
- Percentage of Time Spent at Glycemic Levels <65 mg/dl
- Change in Percentage of Time Spent at Glycemic Levels >180 mg/dl
- Change in Basal Insulin Dose From Baseline Values
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT01341067 |
RMDC-001 |
DexlonT2 |
April 2011 |
December 2011 |
December 2011 |
April 25, 2011 |
May 2, 2014 |
May 2, 2014 |
- Rocky Mountain Diabetes and Osteoporosis Center
Idaho Falls, Idaho, United States
|
|
| 25 |
NCT01084824 |
Completed |
A Trial Examining the Treatment of Common Warts With Combination Liquid Nitrogen (LN2) and Cantharidin |
|
- Drug: Liquid nitrogen and cantharidin
- Drug: Liquid nitrogen and topical placebo
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of common warts cleared
|
70 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01084824 |
NID-001 |
|
June 2007 |
June 2008 |
September 2008 |
March 11, 2010 |
March 11, 2010 |
|
- North Idaho Dermatology
Coeur D'Alene, Idaho, United States
|
|
| 26 |
NCT01055444 |
Completed |
Study Evaluating Heated Lidocaine/Tetracaine Topical Patch in Treatment of Patients With Shoulder Impingement Syndrome |
- Shoulder Impingement Syndrome
|
- Drug: Heated lidocaine and tetracaine topical patch
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pain intensity
- Pain interference with activities (general, normal work, and sleep)
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT01055444 |
SC-202 |
|
March 2010 |
August 2010 |
September 2010 |
January 25, 2010 |
March 16, 2012 |
|
- Injury Care Medical Center
Boise, Idaho, United States
|
|
| 27 |
NCT00925353 |
Completed
Has Results |
The Pharmacokinetics of 4% Lidocaine Gel When Applied Topically to the Breasts |
|
|
Interventional
|
Phase 4 |
- Mountain States Tumor and Medical Research Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pharmacokinetic Parameters Based on Plasma Concentration of Lidocaine and MEGX in Nanograms/Milliliter.
- EKG Changes
- Variation of Heart Rate (Bpm), Respiratory Rate (Respirations Per Minute, Rpm), Systolic Blood Pressure (mm Hg), and Diastolic Blood Pressure (mm Hg) Over Time.
- Frequencies of Moderate, Severe, or Life-threatening Side Effects
|
13 |
Female |
35 Years and older (Adult, Older Adult) |
NCT00925353 |
MSTMRI-002 |
|
January 2010 |
February 2010 |
February 2010 |
June 22, 2009 |
December 23, 2013 |
December 23, 2013 |
- St. Luke's Mountain States Tumor Institute
Boise, Idaho, United States
|
|
| 28 |
NCT00780741 |
Completed
Has Results |
Immediate Office Probing vs Deferred Facility Probing for Nasolacrimal Duct Obstruction in Children 6 to <10 Months Old |
- Nasolacrimal Duct Obstruction
|
- Procedure: Immediate Office Probing
- Procedure: Deferred Facility Probing
|
Interventional
|
Phase 3 |
- Jaeb Center for Health Research
- National Eye Institute (NEI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of Participants With Treatment Success
- Cost of Treatment
- Months of Symptoms of Nasolacrimal Duct Obstruction (NLDO) Between Randomization and 18 Months of Age
- (and 2 more...)
|
220 |
All |
6 Months to 10 Months (Child) |
NCT00780741 |
NEI-142
2U10EY011751 |
NLD3 |
October 2008 |
November 2011 |
January 2012 |
October 28, 2008 |
June 24, 2016 |
November 12, 2012 |
- Intermountain Eye Centers
Boise, Idaho, United States
|
|
| 29 |
NCT00426933 |
Completed |
Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections |
|
- Drug: Daptomycin
- Drug: Vancomycin
|
Interventional
|
Phase 2 |
- Cubist Pharmaceuticals LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical Response Rate at TOC
- difference between clinical response rates at EOT
- microbiological eradication rates
|
100 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT00426933 |
DAP-HDSD-06-01 |
|
January 2007 |
September 2007 |
September 2007 |
January 25, 2007 |
September 14, 2010 |
|
- Idaho Falls Infectious Diseases, PLLC
Idaho Falls, Idaho, United States
|
|
| 30 |
NCT00382083 |
Completed |
Premedication to Reduce Discomfort With Screening Mammography |
|
- Drug: 1000 mg acetaminophen
- Drug: 800 mg ibuprofen
- Drug: 1 oz 4% lidocaine gel
|
Interventional
|
Phase 4 |
- Mountain States Tumor and Medical Research Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Discomfort scores on a visual analog scale at recruitment, at enrollment, and after mammogram
- Satisfaction scores on a visual analog scale after mammogram
- Pre-mammogram anxiety scores on a visual anxiety scale at enrollment
- Pre-mammogram breast tenderness scores on a visual analog scale at enrollment
|
|
Female |
30 Years and older (Adult, Older Adult) |
NCT00382083 |
MSTMRI - 001 |
|
March 2006 |
|
June 2006 |
September 28, 2006 |
September 28, 2006 |
|
- St. Luke's Mountain States Tumor Institute Breast Cancer Detection Center
Boise, Idaho, United States
|
|
| 31 |
NCT03632759 |
Recruiting |
Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D |
|
- Drug: Liraglutide
- Drug: Golimumab
|
Interventional
|
Early Phase 1 |
- Carla Greenbaum, MD
- Juvenile Diabetes Research Foundation
- Benaroya Research Institute
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Proportion of individuals with peak MMTT stimulated C-peptide >0.017 pmol/mL.
|
30 |
All |
18 Years to 50 Years (Adult) |
NCT03632759 |
IRB18-044 |
|
August 15, 2018 |
April 2020 |
June 2020 |
August 15, 2018 |
April 15, 2019 |
|
- Rocky Mountain Diabetes and Osteoporosis Center
Idaho Falls, Idaho, United States - Benaroya Research Institute
Seattle, Washington, United States
|
|
| 32 |
NCT02925442 |
Active, not recruiting |
Genicular Radiofrequency Ablation for Unilateral Knee Arthroplasty Pain Management |
- Osteoarthritis of the Knee
|
- Procedure: t-RFA
- Procedure: C-RFA
- Procedure: Control
|
Interventional
|
Not Applicable |
- Lyman Medical Research Foundation, Inc.
- Halyard Health
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Postoperative analgesic consumption
- Hospital Length of Stay (LOS)
- Pain Score
|
150 |
All |
40 Years and older (Adult, Older Adult) |
NCT02925442 |
OSI-0002 |
RFA |
January 25, 2017 |
January 7, 2020 |
February 7, 2020 |
October 5, 2016 |
May 24, 2019 |
|
- Orthopedic Specialty Institute
Coeur d'Alene, Idaho, United States - Orthopedic Specialty Institute
Spokane, Washington, United States
|
|
| 33 |
NCT02021955 |
Completed |
Integrating Care After Exacerbation of COPD |
- Chronic Obstructive Pulmonary Disease
|
- Behavioral: guideline treatment recommendations
|
Interventional
|
Not Applicable |
- VA Office of Research and Development
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- hospital re-admission and mortality
- patient quality-of-life
|
362 |
All |
Child, Adult, Older Adult |
NCT02021955 |
IIR 12-130 |
InCasE |
February 11, 2015 |
November 29, 2018 |
January 31, 2019 |
December 27, 2013 |
March 8, 2019 |
|
- Boise VA Medical Center, Boise, ID
Boise, Idaho, United States - VA Puget Sound Health Care System Seattle Division, Seattle, WA
Seattle, Washington, United States
|
|
| 34 |
NCT01839864 |
Withdrawn |
Utilizing a Promotora Model for Rural Adult Hispanics Diagnosed With Metabolic Syndrome: A Clinical Trial |
|
- Behavioral: Promotora plus standard physical screening exam , hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count
|
Interventional
|
Not Applicable |
- Family Medicine Residency of Idaho
- Mountain States Group
- Saint Alphonsus Medical Group
- Quantified, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: Triple (Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Patient Activation Measure from baseline to six months and six months to one year
- Changes in patient attitudes about providers and carefrom baseline to six months and six months to one year
|
0 |
All |
18 Years and older (Adult, Older Adult) |
NCT01839864 |
FMRI Promotora Trial |
FMRIMetSynd |
September 2013 |
June 2016 |
August 2016 |
April 25, 2013 |
February 14, 2017 |
|
- Saint Alphonsus Medical Group Caldwell Clinic
Caldwell, Idaho, United States - Saint Lukes Clinic Jerome
Jerome, Idaho, United States - St Alphonsus Medical Group Nampa Clinic
Nampa, Idaho, United States
|
|
| 35 |
NCT02109107 |
Completed
Has Results |
Study of Low Level Laser Light Therapy on Circumference Reduction |
|
- Device: Erchonia EZ6 Laser
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Combined Circumference Measurements
- Change in Body Weight
- Change in Body Mass Index (BMI)
- Subject Satisfaction With Study Outcome Rating
|
54 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02109107 |
EC_EZ6_BC_001 |
|
October 2013 |
November 2014 |
November 2014 |
April 9, 2014 |
February 2, 2016 |
February 2, 2016 |
- Advanced Gynecology Specialists of Augusta, LLC
Evans, Georgia, United States - CT Dermatology PC
Fruitland, Idaho, United States
|
|
| 36 |
NCT01835743 |
Completed
Has Results |
Study of Low Level Laser Therapy to Treat Chronic Heel Pain Arising From Plantar Fasciitis |
|
- Device: Erchonia HPS Laser
- Device: Placebo Laser
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of Participants Who Attained a Change of -30% or Greater in the VAS Score
- Change in Heel Pain Score on the Visual Analog Scale (VAS)
|
69 |
All |
18 Years and older (Adult, Older Adult) |
NCT01835743 |
EC_HP_001 |
|
February 2012 |
May 2012 |
May 2013 |
April 19, 2013 |
June 3, 2014 |
June 3, 2014 |
- Arizona Institute of Footcare Physicians
Mesa, Arizona, United States - Coughlin Foot and Ankle Clinic
Boise, Idaho, United States
|
|
| 37 |
NCT01704157 |
Completed |
A Prospective Study Evaluating the Treatment of Knee Osteoarthritis With the Cryo-Touch III Device |
- Osteoarthritis of the Knee
|
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- An improvement in the Visual Analog Scale (VAS) for pain at Day 7
- Improvement (pain, stiffness, and functionality) as determined by WOMAC Scale at Day 7.
- Duration of Treatment Effect
- Analgesic Use
|
33 |
All |
18 Years and older (Adult, Older Adult) |
NCT01704157 |
MYO-0601
Pain-OA |
|
September 2012 |
April 2013 |
July 2013 |
October 11, 2012 |
January 29, 2014 |
|
- Neurovations
Napa, California, United States - Injury Care Medical Center
Boise, Idaho, United States
|
|
| 38 |
NCT00129831 |
Completed |
Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD) |
|
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety variables (laboratory tests, ECG, adverse events)
- Lung function tests
- Pharmacokinetics
|
6 |
All |
40 Years to 75 Years (Adult, Older Adult) |
NCT00129831 |
CQAB149B2202 |
|
September 2004 |
September 2005 |
September 2005 |
August 12, 2005 |
October 25, 2011 |
|
- Radiant Research
Encinitas, California, United States - Radiant Research
Boise, Idaho, United States
|
|
| 39 |
NCT03015805 |
Recruiting |
Teen Success Project |
|
- Behavioral: Contingency Management
- Behavioral: Probation as Usual
|
Interventional
|
Not Applicable |
- Oregon Social Learning Center
- George Mason University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Changes from Baseline scores compared to 9 months post-Baseline Urine Drug Screens (measured at 0, 3, 6 and 9 months).
- Changes from Baseline scores compared to 9 months post-Baseline Substance Use and Problems (measured at 0, 3, 6 and 9 months).
- Changes in number and severity of criminal charges in official records in the 18 months pre-Baseline compared with 18 months post-Baseline.
- (and 8 more...)
|
540 |
All |
12 Years to 17 Years (Child) |
NCT03015805 |
R01DA041434-01 |
JPO-CM |
October 1, 2017 |
November 2019 |
January 2021 |
January 10, 2017 |
April 5, 2018 |
|
- Mini-Cassia Juvenile Probation
Rupert, Idaho, United States - Twin Falls Juvenile Probation
Twin Falls, Idaho, United States - Washoe County Juvenile Probation
Reno, Nevada, United States
|
|
| 40 |
NCT03749447 |
Recruiting |
An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) |
- Chronic Kidney Diseases
- Alport Syndrome
|
|
Interventional
|
Phase 3 |
- Reata Pharmaceuticals, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Long-term safety: by incidence of adverse events and serious adverse events
|
180 |
All |
12 Years to 65 Years (Child, Adult, Older Adult) |
NCT03749447 |
402-C-1803 |
EAGLE |
March 8, 2019 |
February 2024 |
February 2024 |
November 21, 2018 |
March 28, 2019 |
|
- Denver Nephrologists PC
Denver, Colorado, United States - Boise Kidney & Hypertension, PLLC
Caldwell, Idaho, United States - Boise Kidney & Hypertension, PLLC
Meridian, Idaho, United States
|
|
| 41 |
NCT02351115 |
Completed |
Staccato Alprazolam and Photoparoxysmal Response |
|
- Drug: Staccato® Alprazolam, 0.5 mg
- Drug: Staccato® Alprazolam, 1 mg
- Drug: Staccato® Alprazolam, 2 mg
- (and 2 more...)
|
Interventional
|
Phase 2 |
- Alexza Pharmaceuticals, Inc.
- The Epilepsy Study Consortium
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in the photosensitivity response in subjects receiving Staccato® Alprazolam as compared to placebo
- Assessment of sedation using 2 visual analogue scales
- Correlation of plasma concentrations of Staccato® Alprazolam with pharmacodynamic effects on photosensitivity response
- Correlation of plasma concentrations of Staccato® Alprazolam with pharmacodynamic effects on sedation
|
5 |
All |
18 Years to 60 Years (Adult) |
NCT02351115 |
AMDC-002-202 |
|
January 2015 |
March 2016 |
March 2016 |
January 30, 2015 |
March 15, 2017 |
|
- Consultants in Epilepsy & Neurology, PLLC
Boise, Idaho, United States - New York University Epilepsy Center
New York, New York, United States - University of Pennsylvania - Penn Epilepsy Center
Philadelphia, Pennsylvania, United States
|
|
| 42 |
NCT03959423 |
Recruiting
New |
Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System |
|
- Device: AHCL insulin pump system
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in HbA1c
- Change in percentage of Euglycemia
- Number of Severe Hypoglycemic Event
- Number of Diabetic Ketoacidosis (DKA) Event
|
250 |
All |
7 Years to 75 Years (Child, Adult, Older Adult) |
NCT03959423 |
CIP321 |
|
June 7, 2019 |
January 31, 2020 |
July 31, 2020 |
May 22, 2019 |
June 11, 2019 |
|
- SoCal Diabetes
Torrance, California, United States - Rocky Mountain Diabetes Center
Idaho Falls, Idaho, United States - Rainier Clinical Research
Renton, Washington, United States
|
|
| 43 |
NCT01831960 |
Completed |
An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris |
|
- Drug: cortexolone 17α-propionate
|
Interventional
|
Phase 2 |
- Intrepid Therapeutics, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in HPA Axis Response to Cosyntropin
- Change in PK profiles of cortexolone 17α-propionate and cortexolone
|
42 |
All |
12 Years and older (Child, Adult, Older Adult) |
NCT01831960 |
171-7151-202 |
|
April 2013 |
November 2013 |
November 2013 |
April 15, 2013 |
April 16, 2015 |
|
- Northwest Clinical Trials, Inc.
Boise, Idaho, United States - Shideler Clinical Research Center
Carmel, Indiana, United States - Michigan Center for Research Corp.
Clinton Township, Michigan, United States
|
|
| 44 |
NCT01175889 |
Unknown † |
Megadyne Ace Incision/Dissection Study |
- Abdominoplasty
- Bilateral Breast Reduction
- Bilateral Breast Lift
- (and 2 more...)
|
- Device: E-Z Clean ACE Blade
|
Interventional
|
Phase 4 |
- Megadyne Medical Products Inc.
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Evaluate Wound Healing/Scar Formation
- Evaluate patient satisfaction relating to wound healing
|
52 |
All |
18 Years to 60 Years (Adult) |
NCT01175889 |
ACE MS 1 |
ACE |
August 2010 |
December 2012 |
December 2012 |
August 5, 2010 |
October 25, 2012 |
|
- Center for Plastic Surgery
Twin Falls, Idaho, United States - Southwest Surgical Suites, LLC
Fort Wayne, Indiana, United States - Plastic and Reconstructive Surgery University Health Sciences
Winston-Salem, North Carolina, United States
|
|
| 45 |
NCT00860093 |
Terminated |
Efficacy and Safety of Using MPC-5971 in Subjects Undergoing Shock Wave Lithotripsy |
|
- Other: placebo
- Drug: MPC-5971
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- stone free rate after SWL treatment
- increase in urine inhibitors
- Reduced need for secondary procedures such as URS to clear obstructive fragments
- reduced stone/fragment area (mm2),percent change from the treatment stone area (mm2)
|
135 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT00860093 |
MPC-5971 |
|
April 2010 |
November 2010 |
December 2010 |
March 11, 2009 |
March 7, 2019 |
|
- Idaho Urologic Institute
Meridian, Idaho, United States - Columbus Urology Research
Columbus, Ohio, United States - Urology Clinics of North Texas, PA
Dallas, Texas, United States
|
|
| 46 |
NCT03502174 |
Completed |
FreeStyle Libre Glucose Monitoring System in Pediatric Populations |
|
- Device: FreeStyle Libre Flash Glucose Monitoring System
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- FreeStyle Libre Flash Glucose Monitoring System Performance
- FreeStyle Libre Flash Glucose Monitoring System Related adverse device effects
|
63 |
All |
6 Years to 17 Years (Child) |
NCT03502174 |
ADC-US-VAL-18172 |
|
April 5, 2018 |
July 3, 2018 |
July 3, 2018 |
April 18, 2018 |
January 28, 2019 |
|
- Sansum Diabetes Research Institute
Santa Barbara, California, United States - Diablo Clinical Research
Walnut Creek, California, United States - Rocky Mountain Diabetes & Osteoporosis Center
Idaho Falls, Idaho, United States
|
|
| 47 |
NCT01753765 |
Completed |
Study Evaluating the Treatment of Occipital Neuralgia |
|
- Device: Device: Cryo-Touch III Study treatment at Day 0.
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- A reduction in either pain frequency or severity associated with occipital neuralgia.
- Duration of treatment
- Analgesic use
- Safety Events
|
26 |
All |
18 Years and older (Adult, Older Adult) |
NCT01753765 |
MYO-0613 |
|
October 2012 |
December 2013 |
July 2014 |
December 20, 2012 |
October 21, 2015 |
|
- Neurovations
Napa, California, United States - Injury Care Medical Center
Boise, Idaho, United States - International Clinical Research
Overland Park, Kansas, United States
|
|
| 48 |
NCT00328445 |
Completed |
Randomized Trial of the Positive Action Program in Hawaii Schools |
- Character
- Violence
- Substance Use
- (and 2 more...)
|
- Behavioral: Positive Action
|
Interventional
|
Not Applicable |
- National Institute on Drug Abuse (NIDA)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Self-reported attitudes and behaviors
- Teacher reports of behaviors
- Parent reports of student behaviors
- (and 3 more...)
|
2500 |
All |
6 Years and older (Child, Adult, Older Adult) |
NCT00328445 |
R01DA013474 |
|
April 2001 |
June 2006 |
June 2006 |
May 22, 2006 |
January 12, 2017 |
|
- Positive Action, Inc.
Twin Falls, Idaho, United States - University of Illinois at Chicago
Chicago, Illinois, United States - Oregon State University
Corvallis, Oregon, United States
|
|
| 49 |
NCT00717522 |
Terminated
Has Results |
Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma |
|
|
Interventional
|
Phase 2 |
- Celgene Corporation
- Celgene
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, or Discontinuations Due to AEs
- Tumor Response as Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee Guidelines
|
7 |
All |
18 Years and older (Adult, Older Adult) |
NCT00717522 |
CC-4047-STSAR-001 |
|
August 2008 |
January 2009 |
January 2009 |
July 17, 2008 |
April 16, 2013 |
April 16, 2013 |
- Sarcoma Oncology Center
Santa Monica, California, United States - Kootenai Cancer Center
Couer D' Alene, Idaho, United States - Nebraska Methodist Hospital
Omaha, Nebraska, United States
|
|
| 50 |
NCT03970837 |
Recruiting
New |
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) |
|
- Biological: GSK3196165
- Drug: Tofacitinib
- Drug: Placebo to GSK3196165
- (and 2 more...)
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Proportion of participants achieving 20% improvement in American College of Rheumatology Criteria (ACR20) at Week 12: superiority comparison with placebo
- Proportion of participants achieving Clinical disease activity index (CDAI) total score <=10 [CDAI Low disease activity (LDA)] at Week 12
- Change from Baseline in health assessment questionnaire - disability index (HAQ-DI) at Week 12
- (and 69 more...)
|
1500 |
All |
18 Years and older (Adult, Older Adult) |
NCT03970837 |
201791 |
|
June 4, 2019 |
July 2, 2021 |
May 19, 2022 |
June 3, 2019 |
June 17, 2019 |
|
- GSK Investigational Site
Idaho Falls, Idaho, United States - GSK Investigational Site
Grand Blanc, Michigan, United States - GSK Investigational Site
Houston, Texas, United States - GSK Investigational Site
Tomball, Texas, United States
|
|
| 51 |
NCT03445013 |
Completed |
A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis |
|
- Drug: SB414 6%
- Drug: Vehicle
|
Interventional
|
Phase 1 |
- Novan, Inc.
- Novella Clinical
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Plasma concentrations of hMAP3
- Safety Profile (Reported Adverse Events)
- Subject Assessment of Tolerability
- (and 4 more...)
|
36 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03445013 |
NI-PS101 |
|
October 13, 2017 |
January 31, 2018 |
February 6, 2018 |
February 26, 2018 |
March 27, 2018 |
|
- Novella Site# 247
Boise, Idaho, United States - Novella Site# 183
Austin, Texas, United States - Novella Site# 249
College Station, Texas, United States - Novella Site# 114
Norfolk, Virginia, United States
|
|
| 52 |
NCT02375815 |
Completed |
Statin Choice Decision Aid Implementation First Phase |
- Cardiovascular Factor Risk
|
- Other: Statin Choice Implementation
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Effective Implementation of Statin Choice Decision Aid (SCDA), as indicated by the cumulative reach (% usage in appropriate primary care consultations) across all 3 health systems (as measured by EMR-based calculations).
|
313 |
All |
18 Years and older (Adult, Older Adult) |
NCT02375815 |
14-006048 |
SCIP1 |
January 2015 |
December 2016 |
March 2017 |
March 3, 2015 |
March 24, 2017 |
|
- Kootenai Health
Coeur d'Alene, Idaho, United States - Mayo Clinic in Rochester
Rochester, Minnesota, United States - Mosaic Life Care
St. Joseph, Missouri, United States - Altru Health System
Grand Forks, North Dakota, United States
|
|
| 53 |
NCT03382405 |
Recruiting |
Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults |
- Cytomegalovirus Infection
|
- Biological: mRNA-1647
- Biological: mRNA-1443
- Other: Placebo
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Frequency of solicited AEs (local and systemic reactogenicity events)
- Frequency of unsolicited adverse events
- Frequency of medically-attended AEs, adverse events of special interest (AESI), and serious adverse events (SAE)
- (and 5 more...)
|
226 |
All |
18 Years to 49 Years (Adult) |
NCT03382405 |
mRNA-1647/mRNA-1443-P101 |
|
November 13, 2017 |
July 2020 |
July 2020 |
December 22, 2017 |
March 27, 2019 |
|
- Research Centers of America
Hollywood, Florida, United States - Advanced Clinical Research
Meridian, Idaho, United States - Optimal Research
Peoria, Illinois, United States - Johnson County Clinical Trials
Lenexa, Kansas, United States
|
|
| 54 |
NCT02696252 |
Completed |
G5® Mobile Continuous Glucose Monitoring System Automated vs. Manual Sensor Applicator |
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- proportion of blood glucose values, compared between CGM and a lab glucose analyzer that are matched relative to a diabetes accuracy measurement of %20/20 mg/dL
|
97 |
All |
2 Years and older (Child, Adult, Older Adult) |
NCT02696252 |
PTL-901800 |
|
January 2016 |
April 2016 |
April 2016 |
March 2, 2016 |
April 14, 2016 |
|
- AMCR Institute
Escondido, California, United States - Rocky Mountain Diabetes and Osteoporosis Center
Idaho Falls, Idaho, United States - Joslin Diabetes Center
Boston, Massachusetts, United States - Clinical Trials of Texas
San Antonio, Texas, United States
|
|
| 55 |
NCT02248636 |
Recruiting |
Cholinesterase Inhibitor Discontinuation |
|
- Drug: Cholinesterase inhibitor
- Drug: Sham discontinuation
|
Interventional
|
Phase 2
Phase 3 |
- VA Office of Research and Development
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Successful completion
- Medical events
- Caregiver burden
- (and 4 more...)
|
100 |
All |
60 Years and older (Adult, Older Adult) |
NCT02248636 |
CLIN-014-13F |
CID |
January 22, 2015 |
October 1, 2019 |
October 1, 2019 |
September 25, 2014 |
May 23, 2019 |
|
- Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR
Little Rock, Arkansas, United States - Boise VA Medical Center, Boise, ID
Boise, Idaho, United States - Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA
Bedford, Massachusetts, United States - VA Puget Sound Health Care System Seattle Division, Seattle, WA
Seattle, Washington, United States
|
|
| 56 |
NCT02196818 |
Recruiting |
A Multi-centre, Prospective Surveillance to Assess Mid-term Performance of the Mpact Cup |
- Osteoarthritis
- Arthritis
- Avascular Necrosis
- (and 2 more...)
|
- Device: Mpact Acetabular Shell
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- The Kaplan-Meier analysis as a measure of implant performance.
- The Harris Hip Score.
- Radiological analysis as a meausure of safety.
|
200 |
All |
Child, Adult, Older Adult |
NCT02196818 |
P01.014.08/00 |
|
March 2013 |
March 2023 |
March 2024 |
July 22, 2014 |
April 10, 2018 |
|
- Vail Orthopedics, P.C.
Denver, Colorado, United States - Saint Alphonsus Regional Medical Center
Boise, Idaho, United States - Illinois Bone & Joint Institute, LLC
Libertyville, Illinois, United States - Jordan Valley Medical Center
West Jordan, Utah, United States
|
|
| 57 |
NCT03840993 |
Recruiting |
Safety and Efficacy Study of MT-2990 in Women With Endometriosis |
|
- Drug: MT-2990
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Mitsubishi Tanabe Pharma Development America, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mean change from Baseline to Week 16 in nonmenstrual pelvic pain using a pain scale ranges from 0 (none) to 3 (severe)
- Mean change from Baseline to Week 16 in dysmenorrhea using a pain scale ranges from 0 (none) to 3 (severe)
- Mean change from Baseline to Week 16 in dyspareunia using a pain scale ranges from 0 (none) to 3 (severe)
|
76 |
Female |
18 Years to 49 Years (Adult) |
NCT03840993 |
MT-2990-A01 |
|
January 15, 2019 |
December 2019 |
May 2020 |
February 15, 2019 |
February 15, 2019 |
|
- Northern California Research Corporation
Sacramento, California, United States - Future Care Solution
Miami, Florida, United States - Advanced Clinical Research - Idaho
Boise, Idaho, United States - Northwest Clinical Research Center
Bellevue, Washington, United States
|
|
| 58 |
NCT03820050 |
Completed |
FreeStyle LIbre Flash Glucose Monitoring System Pediatric Accuracy Study |
|
- Device: Freestyle LIbre Flash Glucose Monitoring System
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
144 |
All |
4 Years to 17 Years (Child) |
NCT03820050 |
ADC-US-VAL-18175 |
|
January 29, 2019 |
June 14, 2019 |
June 14, 2019 |
January 29, 2019 |
June 18, 2019 |
|
- Sansum Diabetes Research Institute
Santa Barbara, California, United States - Barbara Davis Center for Diabetes
Aurora, Colorado, United States - Rocky Mountain Diabetes and Osteoporosis Center
Idaho Falls, Idaho, United States - Diabetes and Glandular Disease Clinic
San Antonio, Texas, United States
|
|
| 59 |
NCT03257501 |
Completed |
FreeStyle Libre Flash Accuracy Study |
|
- Device: FreeStyle Libre Flash Glucose Monitoring System
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- System Performance with respect to YSI reference venous plasma sample measurements.
- System Related adverse device effects
|
104 |
All |
18 Years and older (Adult, Older Adult) |
NCT03257501 |
ADC-US-VAL-17166 |
|
August 22, 2017 |
January 8, 2018 |
January 8, 2018 |
August 22, 2017 |
January 9, 2018 |
|
- William Sansum Diabetes Center
Santa Barbara, California, United States - Diablo Clinical Research
Walnut Creek, California, United States - Rocky Mountain Diabetes & Osteoporosis Center
Idaho Falls, Idaho, United States - Rainier Clinical Research
Renton, Washington, United States
|
|
| 60 |
NCT03159546 |
Completed |
FreeStyle Libre Flash Glucose Monitoring System Accuracy |
|
- Device: Device: FreeStyle Libre Flash Glucose Monitoring System
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- System Performance
- System Related adverse device effects
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT03159546 |
ADC-US-VAL-17165 |
|
May 13, 2017 |
July 18, 2017 |
August 24, 2017 |
May 18, 2017 |
September 6, 2017 |
|
- William Sansum Diabetes Center
Santa Barbara, California, United States - Diablo Clinical Research
Walnut Creek, California, United States - Rocky Mountain Diabetes & Osteoporosis Center
Idaho Falls, Idaho, United States - Rainier Clinical Research Center
Renton, Washington, United States
|
|
| 61 |
NCT03141892 |
Completed |
FreeStyle Libre Flash Glucose Monitoring System Accuracy Study |
|
- Device: FreeStyle Libre Flash Glucose Monitoring System
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- System Performance
- System related adverse device effects and serious adverse effects
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT03141892 |
ADC-US-VAL-17164 |
|
April 13, 2017 |
May 23, 2017 |
May 30, 2017 |
May 5, 2017 |
July 11, 2017 |
|
- William Sansum Diabetes Center
Santa Barbara, California, United States - Diablo Clinical Research
Walnut Creek, California, United States - Rocky Mountain Diabetes & Osteoporosis Center
Idaho Falls, Idaho, United States - Rainier Clinical Research Center
Renton, Washington, United States
|
|
| 62 |
NCT02662842 |
Completed |
BD FlowSmart™ Subcutaneous Insulin Infusion Set User Preference and Claims Study |
|
- Device: FlowSmart Infusion Set
- Device: Current Infusion Set
|
Observational
|
|
- Becton, Dickinson and Company
- Medtronic
|
Industry |
- Observational Model: Case-Crossover
- Time Perspective: Prospective
|
- Comparative Infusion Set Insertion Pain
- Comparative Infusion Set Wear Comfort
- Overall Infusion Set Preference
|
75 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02662842 |
DBC-15SCARL15 |
|
January 2016 |
February 2016 |
February 2016 |
January 26, 2016 |
April 13, 2017 |
|
- AMCR Institute Inc.
Escondido, California, United States - Atlanta Diabetes Associates
Atlanta, Georgia, United States - Rocky Mountain Diabetes and Osteoporosis Center
Idaho Falls, Idaho, United States - TKL Research
Fair Lawn, New Jersey, United States
|
|
| 63 |
NCT01040858 |
Completed
Has Results |
Cognitive Rehabilitation of Operations Iraqi Freedom and Enduring Freedom (OIF/OEF) Veterans With Cognitive Disorder |
|
- Behavioral: Cognitive Strategy Training
- Other: Placebo comparison group
|
Interventional
|
Not Applicable |
- US Department of Veterans Affairs
- VA Office of Research and Development
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Multiple Sclerosis Neuropsychological Screening Questionnaire-Patient Version
- Prospective-Retrospective Memory Questionnaire (PRMQ; Crawford, Henry, Ward, &
- The Neurobehavioral Symptom Inventory
- (and 9 more...)
|
128 |
All |
18 Years and older (Adult, Older Adult) |
NCT01040858 |
D7217-R
IRB#2277 |
CROVCD |
May 2011 |
May 2013 |
September 2013 |
December 30, 2009 |
January 26, 2015 |
January 26, 2015 |
- VA San Diego Healthcare System, San Diego
San Diego, California, United States - VA Medical Center, Boise
Boise, Idaho, United States - VA Medical Center, Portland
Portland, Oregon, United States - VA Puget Sound Health Care System, Seattle
Seattle, Washington, United States
|
|
| 64 |
NCT00715273 |
Active, not recruiting |
Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication |
- Coronary Artery Disease
- Carotid Artery Diseases
- Atherosclerosis
|
- Drug: Atorvastatin
- Drug: Niacin
- Drug: Colesevelam
- (and 2 more...)
|
Interventional
|
Phase 4 |
- University of Washington
- National Heart, Lung, and Blood Institute (NHLBI)
- Pfizer
- (and 3 more...)
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
- Changes in carotid plaque composition, as assessed by MRI
- Composite of cardiovascular disease death, non-fatal heart attack, stroke, and worsening ischemia requiring medical interventions
|
217 |
All |
21 Years to 70 Years (Adult, Older Adult) |
NCT00715273 |
STUDY00001165
R01HL063895-05A1 |
CPC |
June 2001 |
March 2019 |
April 2019 |
July 15, 2008 |
February 28, 2019 |
|
- University of Southern California
Los Angeles, California, United States - St. Luke's Idaho Cardiology
Boise, Idaho, United States - University of Washington Coronary Atherosclerosis Research Lab
Seattle, Washington, United States - Yakima Heart Center
Yakima, Washington, United States
|
|
| 65 |
NCT01475760 |
Completed |
A Study to Evaluate Chitosan Chewing Gum in Patients With Chronic Kidney Disease |
|
- Other: K2CG chewing gum (20mg chitosan)
- Other: K2CG chewing gum (60mg chitosan)
|
Interventional
|
Not Applicable |
- Denver Nephrologists, P.C.
- CM&D Pharma Limited
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- serum phosphorus
- salivary phosphorus
|
167 |
All |
18 Years and older (Adult, Older Adult) |
NCT01475760 |
CMD007 |
|
November 2011 |
March 2012 |
March 2012 |
November 21, 2011 |
August 2, 2012 |
|
- Southwest Clinical Reserach Institute, LLC
Tempe, Arizona, United States - Denver Nephrologists, PC
Denver, Colorado, United States - Pacific Renal Research Institute
Meridian, Idaho, United States - Renal Associates, PA
San Antonio, Texas, United States
|
|
| 66 |
NCT02288754 |
Recruiting |
Detection of Tumor DNA in Blood Samples From Cancer Patients |
|
- Diagnostic Test: Blood test
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Correlation between the tumor load score and patient response to therapies.
- Determination of particular mutation events which underlie the basis of any established correlation with therapy response.
|
500 |
All |
18 Years and older (Adult, Older Adult) |
NCT02288754 |
LB1985106 |
|
December 2014 |
November 2019 |
November 2020 |
November 11, 2014 |
August 8, 2018 |
|
- James Sinclair, MD
La Jolla, California, United States - Sharp Clinical Oncology Research
San Diego, California, United States - Cancer Care Associates
Torrance, California, United States - Summit Cancer Center
Post Falls, Idaho, United States
|
|
| 67 |
NCT01514292 |
Completed
Has Results |
Effectiveness and Safety Study of the Dexcom G4™ Continuous Glucose Monitoring System |
|
- Device: Continuous Glucose Monitoring of glucose levels (Dexcom)
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- CGM Relative Differences to Laboratory Reference
|
72 |
All |
18 Years and older (Adult, Older Adult) |
NCT01514292 |
PTL-900590 |
|
December 2011 |
February 2012 |
February 2012 |
January 23, 2012 |
October 5, 2015 |
October 5, 2015 |
- Profil Institute for Clinical Research
Chula Vista, California, United States - AMCR Institute, Inc.
Escondido, California, United States - Diablo Clinical Research
Walnut Creek, California, United States - Rocky Mountain Diabetes and Osteoporosis Center
Idaho Falls, Idaho, United States
|
|
| 68 |
NCT03897595 |
Recruiting |
Assess the Mid-term Performance of the Mpact Cup in Subjects Requiring Total Hip Arthroplasty |
|
- Device: Quadra®-H, Quadra®-C, AMIStem®-H or AMIStem®-C femoral stem and Mpact® Acetabular hip system with CoCr Femoral Head or Ceramic MectaCer BIOLOX® Femoral Head
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from baseline Harris Hip Scores (HHS)
- Change from baseline of implant survivorship
- Change in baseline of Complications
- (and 2 more...)
|
200 |
All |
Child, Adult, Older Adult |
NCT03897595 |
P01.014.08/01 |
|
October 2012 |
December 2022 |
December 2022 |
April 1, 2019 |
April 1, 2019 |
|
- Denver Vail Orthopedics
Parker, Colorado, United States - Saint Alphonsus Medical Group
Boise, Idaho, United States - Illinois Bone and Joint Institute
Libertyville, Illinois, United States - (and 2 more...)
|
|
| 69 |
NCT03686033 |
Recruiting |
A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive Epilepsy |
|
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mean Change from Baseline in the PPR Range in the Most Sensitive Eye Condition (Eye Closure, Eyes Closed, or Eyes Open Condition)
- Mean Change from Baseline in PPR Ranges in Each of the 3 Eye Conditions (Eye Closure, Eyes Closed, and Eyes Open Condition)
- Time to Onset of Photosensitivity Response in Each of the 3 Eye Conditions (Eye Closure, Eyes Closed, and Eyes Open Condition)
- (and 9 more...)
|
9 |
All |
18 Years to 60 Years (Adult) |
NCT03686033 |
E2082-A001-201 |
|
October 31, 2018 |
August 15, 2019 |
August 15, 2019 |
September 26, 2018 |
April 11, 2019 |
|
- Clinical Trials, Inc. and Arkansas Epilepsy Program
Little Rock, Arkansas, United States - Consultants in Epilepsy & Neurology, PLLC
Boise, Idaho, United States - Johns Hopkins University- School of Medicine
Baltimore, Maryland, United States - (and 2 more...)
|
|
| 70 |
NCT03603639 |
Terminated |
A Study to Evaluate the Pharmacodynamic Activity of E2730 in Adult Participants With Photosensitive Epilepsy |
|
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Mean Change from Baseline in the Photoparoxysmal Response (PPR) Range in the Most Sensitive Eye Condition
- Mean Change from Baseline in PPR Ranges in Each of the 3 Eye Conditions (Eye Closure, Eyes Closed, and Eyes Open Condition)
- Time to Onset of Photosensitivity Response in all 3 Eye Conditions (Eye Closure, Eyes Closed, and Eyes Open Condition)
- (and 11 more...)
|
25 |
All |
18 Years to 60 Years (Adult) |
NCT03603639 |
E2730-A001-201 |
|
June 28, 2018 |
February 13, 2019 |
February 13, 2019 |
July 27, 2018 |
May 2, 2019 |
|
- Clinical Trials, Inc. and Arkansas Epilepsy Program
Little Rock, Arkansas, United States - Consultants in Epilepsy & Neurology, PLLC
Boise, Idaho, United States - Johns Hopkins University- School of Medicine
Baltimore, Maryland, United States - (and 2 more...)
|
|
| 71 |
NCT01258595 |
Completed
Has Results |
A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age |
|
- Biological: High-Dose Trivalent Inactivated Influenza Vaccine
- Biological: Trivalent Inactivated Influenza Vaccine
|
Interventional
|
Phase 2 |
- Sanofi Pasteur, a Sanofi Company
- Sanofi
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Geometric Mean Titers (GMTs) of Vaccine Antibodies Before and After Vaccination With Either Fluzone® High-Dose or Fluzone® Vaccine.
- Geometric Mean of Individual Titer Ratios (GMTRs) of Vaccine Antibodies Before and After Vaccination With Either Fluzone® High-Dose or Fluzone® Vaccine
- Percentage of Participants With Seroconversion After Vaccination With Either Fluzone® High-Dose or Fluzone® Vaccine
- (and 2 more...)
|
300 |
All |
50 Years to 64 Years (Adult) |
NCT01258595 |
FIM09
UTN: U1111-1113-3648 |
|
November 2010 |
March 2011 |
April 2011 |
December 13, 2010 |
May 16, 2016 |
October 27, 2011 |
- Idaho Falls, Idaho, United States
- Columbia, Maryland, United States
- Ellicott City, Maryland, United States
- (and 2 more...)
|
|
| 72 |
NCT02061917 |
Completed |
Switching From Usual Brand Cigarettes to a Tobacco-heating Cigarette or Snus |
|
- Other: Tobacco-Heating Cigarette
- Other: Snus (Smokeless Tobacco)
- Other: Tobacco-Burning Cigarette
|
Interventional
|
Not Applicable |
- R.J. Reynolds Tobacco Company
- Analytisch-biologisches Forschungslabor GmbH
- Arista Laboratories
- (and 4 more...)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Urinary Tobacco Exposure Biomarkers from Weeks 0 to 12
- Change in Blood Tobacco Exposure Biomarkers from Weeks 0 to 12
- Change in Markers of Exposure and Potential Harm from Weeks 0 to 12
- (and 15 more...)
|
163 |
All |
28 Years to 55 Years (Adult) |
NCT02061917 |
HSD-0702 |
QoL |
February 2007 |
November 2007 |
November 2009 |
February 13, 2014 |
February 17, 2016 |
|
- Covance Clinical Research Unit, Inc.
Daytona, Florida, United States - Covance Clinical Research Unit, Inc.
Boise, Idaho, United States - Covance Clinical Research Unit, Inc.
Portland, Oregon, United States - (and 2 more...)
|
|
| 73 |
NCT03944941 |
Recruiting |
Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer |
- Skin Squamous Cell Carcinoma
- Metastatic Skin Cancer
|
- Drug: Avelumab
- Drug: Cetuximab
|
Interventional
|
Phase 2 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Prolonging of progression free survival (PFS) on avelumab and cetuximab compared to avelumab alone
- Confirmed objective response rate (RR)
- Clinical benefit rate (CBR)
- (and 3 more...)
|
59 |
All |
18 Years and older (Adult, Older Adult) |
NCT03944941 |
A091802
NCI-2018-02652
U10CA180821 |
|
May 17, 2019 |
December 2022 |
December 2023 |
May 10, 2019 |
June 5, 2019 |
|
- Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, United States - Saint Alphonsus Cancer Care Center-Caldwell
Caldwell, Idaho, United States - Kootenai Medical Center
Coeur d'Alene, Idaho, United States - (and 35 more...)
|
|
| 74 |
NCT03448367 |
Recruiting |
FreeStyle Libre Flash Glucose Monitoring System Post Approval Study for Pediatric Patients |
|
- Device: FreeStyle Libre Flash Glucose Monitoring System
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Safety of the FreeStyle Libre Flash Glucose Monitoring System
|
400 |
All |
4 Years to 17 Years (Child) |
NCT03448367 |
ADC-US-PMS-17168-002 |
|
February 27, 2018 |
February 2021 |
February 2021 |
February 28, 2018 |
June 18, 2019 |
|
- Sansum Diabetes Research Institute
Santa Barbara, California, United States - Barbara Davis Center for Diabetes
Aurora, Colorado, United States - Rocky Mountain Diabetes & Osteoporosis Center
Idaho Falls, Idaho, United States - (and 2 more...)
|
|
| 75 |
NCT00351533 |
Completed
Has Results |
A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI) |
- Respiratory Distress Syndrome, Adult
- Acute Lung Injury
- Acute Respiratory Distress Syndrome
|
- Drug: Fish oil (eicosapentaenoic acid and docosahexanoic acid)
|
Interventional
|
Phase 2 |
- University of Washington
- National Heart, Lung, and Blood Institute (NHLBI)
- American Thoracic Society
- (and 2 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Bronchoalveolar Lavage Fluid (BALF) Interleukin (IL)-8
- Change in BALF Leukotriene B4
- Change in BALF Interleukin-6
- (and 15 more...)
|
90 |
All |
18 Years and older (Adult, Older Adult) |
NCT00351533 |
28503-A
05-7895-A 03 |
|
July 2006 |
January 2009 |
August 2009 |
July 13, 2006 |
October 3, 2011 |
October 3, 2011 |
- St. Alphonsus Medical Center
Boise, Idaho, United States - Oregon Health Sciences University
Portland, Oregon, United States - University of Vermont/Fletcher Allen Health Care
Burlington, Vermont, United States - (and 2 more...)
|
|
| 76 |
NCT03875729 |
Recruiting |
Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab |
|
- Biological: teplizumab
- Biological: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The area under the time-concentration curve (AUC) of C-peptide after a mixed meal tolerance test (MMTT) at Week 78
- Exogenous insulin use
- HbA1c levels
- (and 5 more...)
|
300 |
All |
8 Years to 17 Years (Child) |
NCT03875729 |
PRV-031-001 |
PROTECT |
April 5, 2019 |
May 2022 |
May 2022 |
March 15, 2019 |
June 11, 2019 |
|
- Clinical Site
Walnut Creek, California, United States - Clinical Site
Atlanta, Georgia, United States - Clinical Site
Columbus, Georgia, United States - (and 2 more...)
|
|
| 77 |
NCT03607448 |
Completed |
Freestyle Libre Flash Glucose Monitoring System |
|
- Device: Freestyle Libre Flash Glucose Monitoring System
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- System Performance
- System Related Adverse Device Effects
|
153 |
All |
18 Years and older (Adult, Older Adult) |
NCT03607448 |
ADC-US-VAL-18174 |
|
July 23, 2018 |
November 21, 2018 |
November 21, 2018 |
July 31, 2018 |
November 29, 2018 |
|
- AMCR
Escondido, California, United States - Sansum Diabetes Research Institute
Santa Barbara, California, United States - Diablo Clinical Research
Walnut Creek, California, United States - (and 2 more...)
|
|
| 78 |
NCT02078674 |
Completed |
A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant |
|
- Biological: Monovalent Avian Influenza VLP (H7N9)
- Biological: Matrix-M1™ adjuvant
- Biological: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- Novavax
- Department of Health and Human Services
|
Industry / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Assessment of Safety
- Immunogenicity as assessed by hemagglutination-inhibiting (HAI) antibody titers against the vaccine-homologous A/Anhui/1/13 (H7N9) virus.
- Immunogenicity as assessed by neuraminidase-inhibiting antibodies to N9.
|
610 |
All |
18 Years to 64 Years (Adult) |
NCT02078674 |
FLU-MI7A-201 |
|
March 2014 |
July 2015 |
July 2015 |
March 5, 2014 |
September 23, 2016 |
|
- Diablo Clinical Research
Walnut Creek, California, United States - Miami Research Associates
Miami, Florida, United States - Advanced Clinical Research
Meridian, Idaho, United States - (and 2 more...)
|
|
| 79 |
NCT01877395 |
Completed |
Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen |
|
- Biological: Purified Vero Rabies Vaccine (VRVg)
- Biological: Imovax® Rabies: inactivated rabies vaccine
|
Interventional
|
Phase 2 |
- Sanofi Pasteur, a Sanofi Company
- Sanofi
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Number of participants with rabies virus neutralizing antibody (RVNA) titer ≥ 0.5 IU/mL at Day 42 (14 days after the last vaccination of primary vaccination series).
- Number of Participants Reporting Solicited Injection Site Reactions, Solicited Systemic Reactions, Unsolicited Systemic Reactions, and Serious Adverse Events Occurring Throughout the Trial
- Geometric mean titer ratio (GMTR) following vaccination with either Purified Vero Rabies Vaccine, Serum Free or Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post exposure Regimen
|
342 |
All |
18 Years to 64 Years (Adult) |
NCT01877395 |
VRV04
U1111-1117-7447 |
|
June 2013 |
May 2014 |
September 2014 |
June 13, 2013 |
December 3, 2014 |
|
- Pembroke Pines, Florida, United States
- South Miami, Florida, United States
- Boise, Idaho, United States
- (and 2 more...)
|
|
| 80 |
NCT00442169 |
Completed
Has Results |
Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults |
|
- Biological: ChimeriVax-WN02 Low Dose
- Biological: ChimeriVax-WN02 Medium Dose
- Biological: ChimeriVax-WN02 High Dose
- (and 2 more...)
|
Interventional
|
Phase 2 |
- Sanofi Pasteur, a Sanofi Company
- Sanofi
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Number of Participants With Fourfold or Greater Post-vaccination Titers (Seroconversion).
- Number of Viremic Participants Post-vaccination
- Treatment-emergent Adverse Events Reported As Related to Study Treatment in at Least 5% of Participants in Any Active Treatment Group Post-vaccination.
- Geometric Mean Titers of Neutralizing Antibody Titers Pre- and Post-vaccination.
|
208 |
All |
18 Years and older (Adult, Older Adult) |
NCT00442169 |
H-244-003 |
|
December 2005 |
June 2008 |
April 2009 |
March 1, 2007 |
April 14, 2016 |
February 14, 2011 |
- HOPE Research Institute
Phoenix, Arizona, United States - Idaho Infectious Diseases, PLLC
Idaho Falls, Idaho, United States - PRA International Clinical Pharmacology Center
Lenexa, Kansas, United States - (and 2 more...)
|
|
| 81 |
NCT01288586 |
Completed |
Post-Approval Study to Investigate the Long Term (8 Year) Survivorship of STAR Ankle Among Continued Access Study Patients |
|
- Device: Scandinavian Total Ankle Replacement System (STAR Ankle)
|
Observational
|
|
|
Industry |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- The primary objective for this study is to examine the long-term survivorship of the STAR Ankle
- American Orthopaedic Foot and Ankle Society questionnaire will be used to evaluate and monitor the progress of patients following foot and ankle surgery.
|
87 |
All |
18 Years and older (Adult, Older Adult) |
NCT01288586 |
STAR 8 Year |
STAR 8 |
October 5, 2009 |
November 14, 2016 |
November 14, 2016 |
February 2, 2011 |
March 27, 2017 |
|
- Oakland Bone & Joint Specialists
Oakland, California, United States - Foundations of Orthopedic Research and Education
Temple Terrace, Florida, United States - St. Alphonsus Medical Group, Coughlin Foot & Ankle Clinic
Boise, Idaho, United States - (and 2 more...)
|
|
| 82 |
NCT00299520 |
Completed |
Phase 3 Safety and Efficacy Study of I.V. Iclaprim v Linezolid in cSSSI (ASSIST-1) |
- Complicated Skin and Skin Structure Infection
|
- Drug: intravenous iclaprim or intravenous linezolid
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Clinical cure rate (the ratio of number of clinically cured patients to the total number of patients in the population) at 7 to 14 days after the end of therapy
- Microbiological eradication rate at 7-14 days after end of therapy.
- Safety evaluations conducted during the study
|
|
All |
18 Years and older (Adult, Older Adult) |
NCT00299520 |
Protocol No. ICLA-08-CSI1
ASSIST-1 |
|
June 2005 |
|
July 2006 |
March 7, 2006 |
April 4, 2008 |
|
- e-Study Site
National City, California, United States - VA Medical Center
Boise, Idaho, United States - Infectious Disease of Indiana
Indianapolis, Indiana, United States - (and 2 more...)
|
|
| 83 |
NCT03793166 |
Recruiting |
Nivolumab and Ipilimumab Followed by Nivolumab Versus Cabozantinib and Nivolumab in Treating Patients With Metastatic Untreated Renal Cell Cancer |
- Clear Cell Renal Cell Carcinoma
- Metastatic Malignant Neoplasm in Lymph Node
- Metastatic Malignant Neoplasm in the Bone
- (and 4 more...)
|
- Drug: Cabozantinib
- Biological: Ipilimumab
- Biological: Nivolumab
- (and 2 more...)
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Progression-free survival (PFS)
- Complete response (CR) (randomized patients)
- (and 3 more...)
|
1046 |
All |
18 Years and older (Adult, Older Adult) |
NCT03793166 |
NCI-2018-03694
A031704
U10CA180821 |
|
May 9, 2019 |
September 15, 2021 |
September 15, 2021 |
January 4, 2019 |
June 13, 2019 |
|
- Mercy Hospital Fort Smith
Fort Smith, Arkansas, United States - PCR Oncology
Arroyo Grande, California, United States - Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, United States - (and 179 more...)
|
|
| 84 |
NCT01516216 |
Active, not recruiting |
Study of Vitamin D in Untreated Metastatic Colorectal Cancer |
- Metastatic Colorectal Cancer
|
- Drug: FOLFOX + bevacizumab
- Dietary Supplement: Vitamin D
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Progression Free Survival
- Overall Survival
- Objective tumor response rate
- (and 5 more...)
|
120 |
All |
18 Years and older (Adult, Older Adult) |
NCT01516216 |
11-436 |
|
March 2012 |
November 2019 |
June 2020 |
January 24, 2012 |
February 12, 2019 |
|
- Mountain States Tumor Institute at St. Luke's Regional Medical Center
Boise, Idaho, United States - Mountain States Tumor Institute- Fruitland
Fruitland, Idaho, United States - Mountain States Tumor Institute - Meridian
Meridian, Idaho, United States - (and 15 more...)
|
|
| 85 |
NCT03701308 |
Recruiting |
Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy |
|
- Drug: Cytarabine
- Drug: Daunorubicin
- Drug: Uproleselan
|
Interventional
|
Phase 2
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event-free survival (EFS) (Phase II)
- Overall survival (OS) (Phase III)
- EFS rate
- (and 6 more...)
|
670 |
All |
60 Years and older (Adult, Older Adult) |
NCT03701308 |
NCI-2018-02130
A041701
U10CA180821 |
|
January 16, 2019 |
December 1, 2025 |
December 1, 2025 |
October 10, 2018 |
June 13, 2019 |
|
- UC San Diego Moores Cancer Center
La Jolla, California, United States - Delaware Clinical and Laboratory Physicians PA
Newark, Delaware, United States - Helen F Graham Cancer Center
Newark, Delaware, United States - (and 128 more...)
|
|
| 86 |
NCT03971474 |
Recruiting
New |
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) |
- Recurrent Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8
|
- Drug: Docetaxel
- Drug: Gemcitabine
- Drug: Gemcitabine Hydrochloride
- (and 4 more...)
|
Interventional
|
Phase 2 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Investigator assessed-progression-free survival (IA-PFS)
- Duration of response (DOR)
- (and 2 more...)
|
144 |
All |
18 Years and older (Adult, Older Adult) |
NCT03971474 |
S1800A
NCI-2019-00703
U10CA180888 |
|
May 17, 2019 |
February 1, 2023 |
February 1, 2023 |
June 3, 2019 |
June 3, 2019 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 313 more...)
|
|
| 87 |
NCT03866382 |
Recruiting |
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors |
- Bladder Adenocarcinoma
- Bladder Mixed Adenocarcinoma
- Bladder Small Cell Carcinoma
- (and 37 more...)
|
- Drug: Cabozantinib
- Drug: Cabozantinib S-malate
- Biological: Ipilimumab
- Biological: Nivolumab
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate (ORR)
- Duration of response
- Progression-free survival (PFS)
- (and 3 more...)
|
186 |
All |
18 Years and older (Adult, Older Adult) |
NCT03866382 |
NCI-2019-01266
A031702
U10CA180821 |
|
April 12, 2019 |
February 28, 2023 |
February 28, 2023 |
March 7, 2019 |
June 19, 2019 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 235 more...)
|
|
| 88 |
NCT03851445 |
Recruiting |
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer |
- Previously Treated Non-Small Cell Lung Cancer
|
|
Interventional
|
Phase 2
Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Screening Success (Tissue Submission)
- Screening Success (Adequate Tissue)
- Screening Success (Prescreening-to-sub-study Assignment)
- (and 3 more...)
|
5000 |
All |
18 Years and older (Adult, Older Adult) |
NCT03851445 |
LUNGMAP
NCI-2018-01540 |
|
January 28, 2019 |
April 1, 2022 |
April 1, 2022 |
February 22, 2019 |
February 26, 2019 |
|
- Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States - Anchorage Oncology Centre
Anchorage, Alaska, United States - Katmai Oncology Group
Anchorage, Alaska, United States - (and 302 more...)
|
|
| 89 |
NCT03845296 |
Recruiting |
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) |
- Deleterious BRCA1 Gene Mutation
- Deleterious BRCA2 Gene Mutation
- Loss of Heterozygosity
- (and 8 more...)
|
|
Interventional
|
Phase 2 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Investigator assessed progression free survival (PFS)
- Duration of response (DoR)
- Overall survival
- (and 2 more...)
|
80 |
All |
Child, Adult, Older Adult |
NCT03845296 |
S1900A
NCI-2018-02129
U10CA180888 |
|
January 28, 2019 |
July 1, 2021 |
July 1, 2021 |
February 19, 2019 |
May 8, 2019 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States - (and 488 more...)
|
|
| 90 |
NCT03793179 |
Recruiting |
Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer |
- Lung Non-Squamous Non-Small Cell Carcinoma
- PD-L1 Positive
- Stage IIIB Lung Cancer AJCC v8
- (and 2 more...)
|
- Drug: Carboplatin
- Biological: Pembrolizumab
- Drug: Pemetrexed
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Progression-free survival (PFS)
- Best objective response
- (and 2 more...)
|
846 |
All |
18 Years and older (Adult, Older Adult) |
NCT03793179 |
NCI-2018-03695
EA5163
U10CA180820 |
|
February 28, 2019 |
September 30, 2021 |
September 30, 2021 |
January 4, 2019 |
June 18, 2019 |
|
- University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 588 more...)
|
|
| 91 |
NCT03768414 |
Recruiting |
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers |
- Stage III Distal Bile Duct Cancer AJCC v8
- Stage III Gallbladder Cancer AJCC v8
- Stage III Intrahepatic Cholangiocarcinoma AJCC v8
- (and 14 more...)
|
- Drug: Cisplatin
- Drug: Gemcitabine Hydrochloride
- Drug: Nab-paclitaxel
|
Interventional
|
Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Incidence of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
- Progression-free survival (PFS)
- (and 3 more...)
|
268 |
All |
18 Years and older (Adult, Older Adult) |
NCT03768414 |
S1815
NCI-2018-01920
U10CA180888 |
|
December 3, 2018 |
January 1, 2024 |
January 1, 2024 |
December 7, 2018 |
May 13, 2019 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 491 more...)
|
|
| 92 |
NCT03839940 |
Recruiting |
Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer |
|
- Drug: Dexamethasone
- Other: Placebo
- Other: Questionnaire
- (and 2 more...)
|
Interventional
|
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Incidence rate of the mTOR inhibitor-associated stomatitis (mIAS)-related pain based on daily self-reports via the numerical analogue scale
- Severity of mouth pain scores
- Incidence of grade > 2 mIAS as measured by the SWISH trial
- (and 14 more...)
|
279 |
All |
18 Years and older (Adult, Older Adult) |
NCT03839940 |
A221701
NCI-2018-02648
UG1CA189823 |
|
February 15, 2019 |
February 1, 2020 |
September 2022 |
February 15, 2019 |
May 16, 2019 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Mercy Hospital Fort Smith
Fort Smith, Arkansas, United States - PCR Oncology
Arroyo Grande, California, United States - (and 261 more...)
|
|
| 93 |
NCT03737981 |
Recruiting |
Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Older Patients With Untreated Chronic Lymphocytic Leukemia |
- Chronic Lymphocytic Leukemia
|
- Drug: Ibrutinib
- Biological: Obinutuzumab
- Other: Observation
- Drug: Venetoclax
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival (PFS)
- Bone marrow (BM) minimal residual disease (MRD)- complete response (CR) rate
- Overall survival (OS)
- Incidence of adverse events
|
454 |
All |
70 Years and older (Older Adult) |
NCT03737981 |
NCI-2018-02485
A041702
U10CA180821 |
|
January 4, 2019 |
June 1, 2027 |
June 1, 2027 |
November 12, 2018 |
June 18, 2019 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 635 more...)
|
|
| 94 |
NCT03723928 |
Recruiting |
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer |
- Anatomic Stage IV Breast Cancer AJCC v8
- Estrogen Receptor Positive
- HER2/Neu Negative
- (and 3 more...)
|
- Other: Usual care disease monitoring
- Other: Serum Tumor Marker directed disease monitoring
- Other: Quality-of-Life Assessment
- Other: Anxiety Questionnaire Administration
|
Interventional
|
Not Applicable |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Assessment of whether patients monitored with STMDDM have non-inferior overall survival compared with patients monitored with usual care
- Cumulative direct healthcare costs of patients monitored with STMDDM versus usual care
- Assessment of anxiety of patients monitored with STMDDM compared to patients monitored with usual care
- Assessment of quality of life of patients monitored with STMDDM versus patients monitored with usual care
|
1320 |
All |
18 Years and older (Adult, Older Adult) |
NCT03723928 |
S1703
NCI-2018-00090
SWOG-S1703
UG1CA189974 |
|
July 16, 2018 |
July 15, 2027 |
July 15, 2027 |
October 30, 2018 |
December 21, 2018 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States - (and 249 more...)
|
|
| 95 |
NCT03701282 |
Recruiting |
Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia |
- CCND1/IGHG1 Fusion Negative
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- t(11;14) Negative
|
- Drug: Ibrutinib
- Biological: Obinutuzumab
- Other: Quality-of-Life Assessment
- Drug: Venetoclax
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival
- Overall survival
- Incidence of adverse events graded according to Common Terminology Criteria for Adverse Events version 5.0
|
720 |
All |
18 Years to 69 Years (Adult, Older Adult) |
NCT03701282 |
NCI-2018-02127
EA9161
U10CA180820 |
|
January 3, 2019 |
October 31, 2025 |
October 31, 2025 |
October 10, 2018 |
June 18, 2019 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 687 more...)
|
|
| 96 |
NCT03698019 |
Recruiting |
Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery |
- Acral Lentiginous Melanoma
- Clinical Stage III Cutaneous Melanoma AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- (and 7 more...)
|
- Biological: Pembrolizumab
- Procedure: Therapeutic Conventional Surgery
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event-free survival (EFS) in patients with high-risk resectable melanoma randomized to neoadjuvant pembrolizumab with patients randomized to adjuvant pembrolizumab
- Overall survival (OS)
- Disease control
- (and 5 more...)
|
556 |
All |
18 Years and older (Adult, Older Adult) |
NCT03698019 |
NCI-2018-02107
S1801
U10CA180888 |
|
December 6, 2018 |
September 1, 2022 |
September 1, 2022 |
October 5, 2018 |
June 18, 2019 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 624 more...)
|
|
| 97 |
NCT03766009 |
Recruiting |
Increasing Patients' Engagement in Breast Cancer Surgery Decision-Making |
- Breast Cancer Stage 0
- Breast Cancer Stage I
- Breast Cancer Stage II
- Breast Cancer Stage III
|
- Other: Usual Care
- Other: Web-based decision aid
|
Interventional
|
Not Applicable |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Agency for Healthcare Research and Quality (AHRQ)
|
Other / NIH / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Patient power: self-efficacy in patient physician interactions
- Patient power: active patient participation
- Patient knowledge
- Concordance between personal values and surgery received
|
1050 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03766009 |
A231701CD
NCI-2018-00643 |
|
March 1, 2019 |
December 2020 |
December 2022 |
December 5, 2018 |
May 16, 2019 |
|
- Epic Care-Dublin
Dublin, California, United States - Bay Area Breast Surgeons Inc
Emeryville, California, United States - Epic Care Partners in Cancer Care
Emeryville, California, United States - (and 49 more...)
|
|
| 98 |
NCT03660826 |
Active, not recruiting |
Olaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer |
- Endometrial Undifferentiated Carcinoma
- Endometrioid Adenocarcinoma
- Recurrent Endometrial Serous Adenocarcinoma
- (and 4 more...)
|
- Drug: Cediranib Maleate
- Other: Laboratory Biomarker Analysis
- Drug: Olaparib
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival
- Overall survival
- Objective tumor response
|
120 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03660826 |
NCI-2017-01672
NRG-GY012
U10CA180868 |
|
September 4, 2018 |
September 4, 2020 |
September 4, 2020 |
September 7, 2018 |
June 19, 2019 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 629 more...)
|
|
| 99 |
NCT03737994 |
Recruiting |
Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-Small Cell Lung Cancer (The NCI-NRG ALK Master Protocol) |
- ALK Gene Rearrangement
- ALK Positive
- Lung Non-Squamous Non-Small Cell Carcinoma
- (and 3 more...)
|
- Drug: Alectinib
- Drug: Brigatinib
- Drug: Carboplatin
- (and 6 more...)
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Objective response rate (ORR) defined as the number of subjects whose best overall response (BOR) of complete response (CR) or partial response (PR) divided by the number of evaluable subjects per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- Progression-free survival (PFS) according to RECIST 1.1
- Duration of response (DOR) defined by RECIST 1.1
- (and 3 more...)
|
660 |
All |
18 Years and older (Adult, Older Adult) |
NCT03737994 |
NCI-2018-02486
NRG-LU003
U10CA180868 |
|
April 1, 2019 |
December 13, 2025 |
December 13, 2025 |
November 12, 2018 |
June 17, 2019 |
|
- Mercy Hospital Fort Smith
Fort Smith, Arkansas, United States - CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas, United States - Kaiser Permanente-Deer Valley Medical Center
Antioch, California, United States - (and 303 more...)
|
|
| 100 |
NCT00644293 |
Completed |
A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin Sustained Release Versus 3-Day Azithromycin for the Treatment of Strep Throat in Adolescents and Adults |
|
- Drug: azithromycin (Zithromax)
- Drug: placebo
- Drug: azithromycin SR
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- bacteriologic response in the Bacteriologic per Protocol population
- sponsor assessment of clinical response in the Bacteriologic per Protocol population
- bacteriologic response for the remaining study populations
- (and 4 more...)
|
598 |
All |
13 Years and older (Child, Adult, Older Adult) |
NCT00644293 |
A0661119 |
|
January 2003 |
|
April 2004 |
March 26, 2008 |
June 8, 2011 |
|
- Pfizer Investigational Site
Clearwater, Florida, United States - Pfizer Investigational Site
Boise, Idaho, United States - Pfizer Investigational Site
Boise, Idaho, United States - (and 56 more...)
|
|
Create an RSS feed from your search for:
Download the search results for: